Furthermore, multiple studies have reported enhancement of chemotherapy and rituximab sensitivity in human lymphoma/leukemia cells and xenografts when combined with survivin inhibition [18, 39, 47]; however, trials of survivin inhibition in dogs with neoplasia have yet to be reported in the peer-reviewed literature. The gene discussed is BIRC5; the disease is leukemia.